Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Perioperative safety and tolerability of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with concurrent systemic therapy in the same admission as a bidirectional chemotherapy: A retrospective comparative study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Same author

Rare Case of Alopecia: Alopecia Neoplastica.

International journal of trichology·2025

Same author

Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma.

BMJ case reports·2025

Same author

Triple-Negative, HER2/Neu, and Ki67 Markers in Breast Cancer Patients Undergoing Standard of Care Treatment in India: Real-World Evidence on Tumor Aggressiveness and Survival Outcomes.

Cureus·2025

Same author

Real-World Evidence on the Effectiveness of Pembrolizumab in Patients With Recurrent/Metastatic/Unresectable Head and Neck Squamous Cell Cancer: A Systematic Review and Meta-Analysis.

Cureus·2025

Same author

Primary Ewing<sup>'</sup>s Sarcoma of Body of Mandible, Multimodal Treatment with Excellent Spontaneous Bone Regeneration: a Case Report.

Journal of maxillofacial and oral surgery·2023

Search research articles

Related Experiment Video

Updated: Aug 15, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?

Pravesh Dhiman¹, P P Bapsy², C N Patil²

¹Medical Oncology, Department of RT and Oncology, IGMC, Shimla, Himachal Pradesh, India.

South Asian Journal of Cancer

|January 2, 2023

Summary

Optimal cytoreduction after neoadjuvant chemotherapy significantly improves progression-free survival in advanced epithelial ovarian cancer (EOC). This treatment approach is crucial for managing EOC, though further research is needed to confirm overall survival benefits.

Keywords:

cytoreductive surgery epithelial ovarian cancer interval debulking surgery neoadjuvant chemotherapy progression-free survival

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

Related Experiment Videos

Last Updated: Aug 15, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

Area of Science:

Oncology
Gynecologic Oncology
Surgical Oncology

Background:

Epithelial ovarian cancer (EOC) is a leading cause of cancer death in women, with 70% diagnosed at advanced stages (FIGO III-IV).
Advanced EOC carries a poor prognosis, with a 5-year survival rate of only 30%.
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a recognized treatment strategy for advanced EOC.

Purpose of the Study:

To evaluate the correlation between neoadjuvant chemotherapy (NACT) and patient outcomes in advanced epithelial ovarian cancer (EOC).
To assess the impact of cytoreduction extent on progression-free survival (PFS) following NACT and interval debulking surgery (IDS).

Main Methods:

A retroprospective observational study included 50 patients with advanced ovarian cancer diagnosed between January 2012 and January 2017.
Data analyzed included patient profiles, CA125 levels, clinicopathologic parameters, PFS, and treatment response.
Statistical analysis employed log-rank tests and Kaplan-Meier survival plots.

Main Results:

The extent of cytoreduction significantly correlated with progression-free survival (PFS).
Patients achieving optimal cytoreduction had a median PFS of 19 months, compared to 10 months for suboptimal cytoreduction (p < 0.05).
Survival did not significantly correlate with age, stage, preoperative CA125 levels, or ascites.

Conclusions:

Optimal cytoreduction following NACT in advanced EOC is associated with a statistically significant PFS advantage.
NACT followed by interval cytoreduction is an important treatment modality impacting survival in advanced EOC.
Further studies with longer follow-up are required to confirm survival advantages over standard treatments.